Explore the words cloud of the The MATRIX project. It provides you a very rough idea of what is the project "The MATRIX" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||1˙700˙002 €|
|EC max contribution||1˙700˙002 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2019-09-01 to 2024-08-31|
Take a look of project's partnership.
|1||GOETEBORGS UNIVERSITET||SE (GOETEBORG)||coordinator||1˙700˙002.00|
Obesity and its affiliated metabolic diseases pose serious public-health challenges. However, certain patient subgroups appear protected. To halt the socio-economic burden of metabolic disease, we urgently need to understand what distinguishes the Metabolically-Healthy-Lean (MHL), Metabolically-Unhealthy-Lean (MUL), Metabolically-Healthy-Obese (MHO) and Metabolically-Unhealthy-Obese (MUO) phenotypes, and which factors promote metabolic health. Inflammation has been proposed as a target, as it is a key driver of metabolic disease. However, clinical trials show limited evidence that anti-inflammatory drugs reduce diabetes. Why is that?
Inflammation consists of a pro-inflammatory phase followed by a pro-resolving phase, which are regulated by different cells/pathways. This is critical to consider when attempting a therapeutic approach. Based on my preliminary data, I hypothesise that what separates MHL/MHO from MUL/MUO are not pro-inflammatory triggers, but rather the endogenous ability of individuals to resolve inflammation. Adipose extracellular-matrix remodelling appears critical, and pro-resolving lipids promote a MUO-to-MHO switch.
My overall goal is to determine molecular pathways that differentiate the MHL/MUL/MHO/MUO phenotypes (Aim 1-4), and to investigate the therapeutic potential of pro-resolving lipids (Aim 5). This multi-disciplinary project combines cutting-edge techniques with state-of-the-art translational approaches. Through my unique access to human biobanks, I will generate patient-specific cell-lines and test drug-targets ex vivo. Novel bioinformatics pipelines will produce protein/lipid/metabolite fingerprints associated with respective patient groups, ultimately providing a new approach to tackle obesity-related comorbidities. My experience in the specialised field of pro-resolving lipid biology, coupled with my lab’s unique placement at a translational site, makes me the right candidate to lead this research program.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THE MATRIX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THE MATRIX" are provided by the European Opendata Portal: CORDIS opendata.
MRI toolkit for in vivo fat virtual biopsyRead More
Comprehensive anatomical, genetic and functional identification of cerebellar nuclei neurons and their roles in sensorimotor tasksRead More
CApturing Paradata for documenTing data creation and Use for the REsearch of the futureRead More